Fulvestrant in the treatment of hormone receptor-positive advanced breast cancer - A cost-effective addition to the treatment sequence.

被引：0
|
作者：
Cameron, D. A.
Camidge, D. R.
Gait, C.
Hirsch, M.
机构：
[1] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Mapi Values, Cheshire, England
[3] AstraZeneca, Macclesfield, Cheshire, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S231 / S232
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Zhang, Bingnan
    Long, Elisa F.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 775 - 779
  • [42] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Bingnan Zhang
    Elisa F. Long
    Breast Cancer Research and Treatment, 2019, 175 : 775 - 779
  • [43] Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
    Huang, Xiaoting
    Weng, Xiuhua
    Lin, Shen
    Liu, Yiwei
    Luo, Shaohong
    Wang, Hang
    Ming, Wai-kit
    Huang, Pinfang
    BMJ OPEN, 2020, 10 (08):
  • [44] A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222
    Moore, Halle C. F.
    Barlow, William E.
    Somlo, George
    Gralow, Julie R.
    Schott, Anne F.
    Hayes, Daniel F.
    Kuhn, Peter
    Hicks, James B.
    Welter, Lisa
    Dy, Philip A.
    Yeon, Christina H.
    Conlin, Alison K.
    Balcueva, Ernie
    Lew, Danika L.
    Tripathy, Debasish
    Pusztai, Lajos
    Hortobagyi, Gabriel N.
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 611 - 617
  • [45] Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant
    Calhoun, KE
    Pommier, RF
    Muller, P
    Fletcher, WS
    Toth-Fejel, S
    ARCHIVES OF SURGERY, 2003, 138 (08) : 879 - 882
  • [46] Fulvestrant for the treatment of advanced breast cancer
    Blackburn, Sophie A.
    Parks, Ruth M.
    Cheung, Kwok-Leung
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (07) : 619 - 628
  • [47] Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer
    Kaklamani, Virginia G.
    ONCOLOGIST, 2016, 21 (08): : 922 - 930
  • [48] Considerations for payers in managing hormone receptor-positive advanced breast cancer
    Chitre, Mona
    Reimers, Kristen M.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 331 - 339
  • [49] Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer
    Koi, Yumiko
    Koga, Chinami
    Akiyoshi, Sayuri
    Masuda, Takanobu
    Ijichi, Hideki
    Nakamura, Yoshiaki
    Ishida, Mayumi
    Ohno, Shinji
    Tokunaga, Eriko
    ANTICANCER RESEARCH, 2018, 38 (03) : 1579 - 1584
  • [50] Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy
    Chlebowski, Rowan T.
    CLINICAL BREAST CANCER, 2013, 13 (03) : 159 - 166
12345